Advancements in diagnostic tools, such as genetic testing and biomarker analysis, have enabled earlier identification and treatment of cancers, contributing to improved patient survival rates.
For instance, the American Cancer Society reported that cancer death rate declined by 1.5% from 2019 to 2020, contributing to a 33% total reduction since 1991 and resulting in an estimated 3.8 million fewer deaths, due to the significant contribution of early detection and improved treatments. This trend highlights the importance of continued investment in cancer diagnostics and screening programs.
Additionally, many countries are increasing healthcare budgets and offering grants and subsidies for oncology research and treatment facilities. This trend is particularly significant in developing regions and emerging markets like the Middle East and Asia Pacific, where investments are improving access to advanced cancer care.
For instance, the “Health Minister’s Cancer Patient Fund (HMCPF)” under the Rashtriya Arogya Nidhi (RAN) was established to assist impoverished cancer patients in India. It provided financial aid for treatment to patients below the poverty line at 27 Regional Cancer Centers (RCCs). Each RCC was provided access to a revolving fund of up to USD 59,000 to support eligible patients.
These increasing investments in healthcare, grants, and subsidies for oncology are significantly boosting the market. By enhancing access to advanced treatments and providing financial support for cancer patients, particularly in emerging markets, these efforts are expanding the reach of cancer care, fostering demand, and driving market growth in oncology.
Authors:
Mariam Faizullabhoy , Gauri Wani
Frequently Asked Questions (FAQ) :
The global oncology industry was valued at approximately USD 320.3 billion in 2024 and is estimated to grow at a 10.8% CAGR from 2025 to 2034, driven by the increasing number of diagnostic laboratories in developing countries.
The cancer treatment segment dominated the market with the largest revenue share of 54.6% in 2024, due to aging populations, lifestyle-related risks (such as smoking, poor diet, and lack of physical activity), and environmental influences.
The U.S. oncology market is projected to reach USD 377.1 billion by 2034, driven by an aging population and lifestyle factors increasing the demand for oncology services, treatments, and research.
Key players in the global market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GE HealthCare Technologies, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Novartis, Pfizer, and F. Hoffmann-La Roche.